AKORN Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AKORN, and what generic and branded alternatives to AKORN drugs are available?
AKORN has one approved drug.
There are two tentative approvals on AKORN drugs.
Summary for AKORN
| US Patents: | 0 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
| PTAB Cases with AKORN as petitioner: | See PTAB cases with AKORN as petitioner |
Drugs and US Patents for AKORN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Akorn | FAMOTIDINE | famotidine | FOR SUSPENSION;ORAL | 201995-001 | May 30, 2014 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
